



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : <b>C12Q 1/68</b></p>	<b>A1</b>	<p>(11) International Publication Number: <b>WO 97/41257</b></p> <p>(43) International Publication Date: 6 November 1997 (06.11.97)</p>																																	
<p>(21) International Application Number: <b>PCT/US97/07133</b></p> <p>(22) International Filing Date: <b>29 April 1997 (29.04.97)</b></p> <p>(30) Priority Data:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">08/640,672</td> <td style="width: 40%;">1 May 1996 (01.05.96)</td> <td style="width: 30%; text-align: right;">US</td> </tr> <tr> <td>08/684,498</td> <td>19 July 1996 (19.07.96)</td> <td style="text-align: right;">US</td> </tr> <tr> <td>08/807,138</td> <td>27 February 1997 (27.02.97)</td> <td style="text-align: right;">US</td> </tr> </table> <p>(60) Parent Applications or Grants</p> <p>(63) Related by Continuation</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">US</td> <td style="width: 40%;">08/640,672 (CIP)</td> <td style="width: 30%;"></td> </tr> <tr> <td>Filed on</td> <td>1 May 1996 (01.05.96)</td> <td></td> </tr> <tr> <td>US</td> <td>08/684,498 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 July 1996 (19.07.96)</td> <td></td> </tr> <tr> <td>US</td> <td>08/577,858 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>12 December 1995 (12.12.95)</td> <td></td> </tr> <tr> <td>US</td> <td>08/807,138 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>27 February 1997 (27.02.97)</td> <td></td> </tr> </table> <p>(71) Applicant (for all designated States except US): <b>VISIBLE GENETICS INC. [CA/CA]; Box 333, 700 Bay Street, Toronto, Ontario M5G 1Z6 (CA).</b></p>			08/640,672	1 May 1996 (01.05.96)	US	08/684,498	19 July 1996 (19.07.96)	US	08/807,138	27 February 1997 (27.02.97)	US	US	08/640,672 (CIP)		Filed on	1 May 1996 (01.05.96)		US	08/684,498 (CIP)		Filed on	19 July 1996 (19.07.96)		US	08/577,858 (CIP)		Filed on	12 December 1995 (12.12.95)		US	08/807,138 (CIP)		Filed on	27 February 1997 (27.02.97)	
08/640,672	1 May 1996 (01.05.96)	US																																	
08/684,498	19 July 1996 (19.07.96)	US																																	
08/807,138	27 February 1997 (27.02.97)	US																																	
US	08/640,672 (CIP)																																		
Filed on	1 May 1996 (01.05.96)																																		
US	08/684,498 (CIP)																																		
Filed on	19 July 1996 (19.07.96)																																		
US	08/577,858 (CIP)																																		
Filed on	12 December 1995 (12.12.95)																																		
US	08/807,138 (CIP)																																		
Filed on	27 February 1997 (27.02.97)																																		
<p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): <b>LACROIX, Jean-Michel [CA/CA]; 35 Trueman Avenue, Etobicoke, Ontario M8Z 5A3 (CA). LEUSHNER, James [CA/CA]; 84 Sylvan Valley Way, North York, Ontario M5M 4M3 (CA). HUI, May [CA/CA]; 24 Wellesley Street, Toronto, Ontario M4Y 1G1 (CA). DUNN, James, M. [CA/CA]; 117 Citadel Drive, Scarborough, Ontario M1K 2S8 (CA). LARSON, Marina, T. [US/US]; 2322 Vista Court, Yorktown, NY 10598 (US).</b></p> <p>(74) Agent: <b>LARSON, Marina, T.; Oppedahl &amp; Larson, Suite 309, 1992 Commerce Street, Yorktown Heights, NY 10598-4412 (US).</b></p> <p>(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b></p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>																																			
<p>(54) Title: <b>METHOD, COMPOSITIONS AND KIT FOR DETECTION AND IDENTIFICATION OF MICROORGANISMS</b></p> <p>(57) Abstract</p> <p>Evaluation of a sample for the presence and qualitative nature of a microorganism can be performed in a single vessel by combining a natural abundance DNA sample with a sequencing mixture containing a primer pair, a thermally stable polymerase such as ThermoSequenase™ which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than about 0.4 times the rate of incorporation of deoxynucleotides, nucleotide triphosphate feedstocks, and a chain terminating nucleotide triphosphate. The mixture is processed through multiple thermal cycles for annealing, extension and denaturation to produce a product mixture which is analyzed by electrophoresis.</p>																																			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

- 1 -

METHOD, COMPOSITIONS AND KIT FOR  
DETECTION AND IDENTIFICATION OF MICROORGANISMS

DESCRIPTION

BACKGROUND OF THE INVENTION

This application relates to a method for detection and identification of microorganisms, including in particular pathogenic microorganisms, and to compositions and kits useful in practicing the method. The invention can be applied to detection of viruses, including HIV and hepatitis, bacteria, including *Chlamydia*, fungi, including *Cryptococcus neoformans* and protozoa, including *Trypanosoma cruzi*.

Detection of the presence of pathogenic microorganisms through DNA-based technology is emerging as an important tool in the diagnosis of many diseases. For example, diagnosis of *Chlamydia trachomatis* infections, the most common bacterial sexually transmitted disease in North America, is shifting from traditional methods such as culture, enzyme immunoassay (EIA) and direct fluorescent antibodies (DFA) to DNA-hybridization diagnostics. Roche Diagnostic Systems, Inc. (Nutley, NJ) manufactures Amplicor™, a test which detects *C. trachomatis* and *Neisseria gonorrhoeae* by the hybridization of a pathogen specific probe to PCR amplified products, detectable by a color change/optical density technique. Abbott Laboratories (Abbott Park, IL) makes UriProbe, also a test for *C. trachomatis* and *N. gonorrhoeae*, which relies on the ligase chain reaction (LCR). The LCR method, described in Patent Applications WO 9320227, WO 9300447, WO 9408047, WO 9403636, EP 477 972 uses thermostable ligase enzyme to ligate two DNA probes which hybridize in ligatable juxtaposition on a template DNA strand, thus generating a detectable ligated DNA fragment only if the template DNA is present. A multiplex PCR assay for *C. trachomatis* has also been described in Mahony et al., *J. Clin. Microbiol.* 33: 3049-3053 (1995).

A wide variety of infectious pathogens that can be detected by DNA-based methods are listed in *Diagnostic Molecular Microbiology*, Persing et al., eds. American Society for Microbiology, Washington D.C. (1993). This text details diagnostic tests for bacteria, virus, fungi, and protozoa. Diagnostic tests are also proposed for identifying the presence of drug resistance genes or toxin genes.

Although these tests are generally effective for identifying an infectious disease-causing organism if present, they do not routinely provide information concerning the specific serotype,

- 2 -

variant or form of the infecting organism. Depending on the organism in question, this information can be significant in determining the likely course of the infection, for determining the most appropriate therapeutic approach and for epidemiological purposes. Furthermore, the previously known assays involve several steps and are therefore more susceptible to systematic error than would be a test with fewer steps. Thus, there remains a need for a simple test format which is generally applicable to the detection of microorganisms, including infectious disease-causing microorganisms, and particularly for a simple test which provides an indication of the specific nature, e.g., the serotype, of the organism. It is an object of the present invention to provide such a test.

It is a further object of the present invention to provide reagent combinations useful in performing tests for infectious disease-causing microorganisms, including *Chlamydia* human papilloma virus(HPV) and HIV.

It is still a further object of the present invention to provide kits useful in performing tests for infectious disease-causing microorganisms, including *Chlamydia*, HPV and HIV.

#### SUMMARY OF THE INVENTION

The present invention provides a method for the evaluation of a sample for the presence of a target microorganism which can be performed directly on a natural abundance DNA preparation obtained from the sample in a single reaction vessel. The method of the invention comprises the steps of:

(a) combining the natural abundance DNA preparation with first and second primers, a nucleotide triphosphate feedstock mixture, a chain-terminating nucleotide triphosphate and a thermally stable polymerase enzyme which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of deoxynucleotides to form a reaction mixture, said first and second primers binding to the sense and antisense strands of the DNA of the target microorganism, respectively, and flanking a selected region within the genome of the target microorganism;

(b) exposing the reaction mixture to a plurality of temperature cycles each of which includes at least a high temperature denaturation phase and a lower temperature extension phase, thereby producing a plurality of species of terminated fragments if DNA from the target microorganism is present in the sample, each species of terminated fragment corresponding to a

- 3 -

different incorporation position for the chain-terminating nucleotide triphosphate in the DNA of the target microorganism; and

- (c) evaluating the terminated fragments produced to determine the incorporation positions of the chain-terminating nucleotide triphosphate. Based on the incorporation positions, not only the presence but also the specific nature, e.g. the serotype, of any target microorganism present can be determined.

### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a novel approach to the evaluation of a sample for the presence of a target microorganism and for the identification of the specific nature of any organism found to be present. The target microorganism may be virus, bacteria, fungi or protozoa. Specific non-limiting examples of microorganisms to which the invention can be suitably applied include bacteria such as *Mycobacteria tuberculosis*, *Rickettsia rickettsii*, *Ehrlichia chaffeensis*, *Borrelia burgdorferi*, *Yersinia pestis*, *Treponema pallidum*, *Chlamydia trachomatis*, *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, *Mycoplasma sp.*, *Legionella pneumophila*, *Legionella dumoffii*, *Mycoplasma fermentans*, *Ehrlichia sp.*, *Haemophilus influenzae*, *Neisseria meningitidis*, *Streptococcus pneumoniae*, *S. agalactiae*, and *Listeria monocytogenes*; viruses such as Human Immunodeficiency Virus Type 1 (HIV-1), Human T-Cell Lymphotropic Virus Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex, Herpesvirus 6, Herpesvirus 7, Epstein-Barr Virus, Cytomegalovirus, Varicella-Zoster Virus, JC Virus, Parvovirus B19, Influenza A, B and C, Rotavirus, Human Adenovirus, Rubella Virus, Human Enteroviruses, Genital Human Papillomavirus (HPV), and Hantavirus; fungi such as *Cryptococcus neoformans*, *Pneumocystis carinii*, *Histoplasma capsulatum*, *Blastomyces dermatitidis*, *Coccidioides immitis*, and *Trichophyton rubrum*; and protozoa such as *Trypanosoma cruzi*, *Leishmania sp.*, *Plasmodium*, *Entamoeba histolytica*, *Babesia microti*, *Giardia lamblia*, *Cyclospora sp.* and *Eimeria sp.* The method of the invention may also be used for *Cryptosporidium* oocyst detection; for identification of bacterial toxin genes, such as the toxin genes from *Vibrio cholerae* 01, enterotoxigenic *Escherichia coli*, *Shigella sp.*, enteroinvasive *E. coli*, *Helicobacter pylori* (formerly *Campylobacter pylori*), toxigenic *Clostridium difficile*, *Staphylococcus aureus*, and *Streptococcus pyogenes* exotoxins; and for identification of anti-microbial resistance loci such as rifampin resistance mutations in

- 4 -

*Mycobacterium tuberculosis* and *M. leprae*; HIV Drug Resistance, *erm* Erythromycin Resistance Genes, methicillin--resistance genes in *Staphylococcus*, Penicillinase-Producing genes in *Neisseria gonorrhoeae*, genes encoding aminoglycoside-modifying enzymes, genes encoding an extended spectrum of Beta-Lactamases, fluoroquinolone and isoniazid resistance mutations in *Mycobacterium tuberculosis*, and genes encoding vancomycin resistance in Enterococci.

In accordance with the method of the invention, a natural abundance DNA-containing sample suspected to contain the target microorganism is combined in a reaction mixture with (1) first and second primers that hybridize with the sense and antisense strands of the DNA of the target microorganism, respectively, and flank a selected region within the genome of the target microorganism, (2) a nucleotide triphosphate feedstock mixture, (3) at least one chain-terminating nucleotide triphosphate and (4) a polymerase enzyme which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of deoxynucleotides to form a reaction mixture. This reaction mixture is processed through a plurality of thermal cycles. Each thermal cycle includes at least an extension step which is performed at a temperature of around 68 to 75 °C and a denaturation step performed at a temperature of around 90 to 98 °C. In addition, the thermal cycles may include a separate annealing step performed at a temperature of 50 to 70 °C.

During each cycle, the primers each anneal to the respective strand of any target DNA present in the sample, and primer chain extension using the polymerase enzymes and the nucleotide triphosphate feedstocks proceeds until terminated by incorporation of a chain-terminating nucleotide triphosphate. This results in the production of sequencing fragments comparable to those generated in a conventional sequencing reaction. Analysis of these fragments provides information concerning the sequence of the selected region of the target DNA, and thus of the serotype of the target microorganism. Those extension products which are not terminated prior to reaching the region complementary to the other primer can serve as template for generation of sequencing fragments in later cycles, although this generally occurs to a very small extent.

Among the advantages of the present invention is the ability to perform an evaluation directly on a "natural abundance" DNA sample. The nature of the initial sample will depend on the nature of the target microorganism. For example, in the case of *Chlamydia*, the initial sample employed in the present invention is suitably a urine sample, genital scraping or genital

- 5 -

swab taken from a human patient, although other samples which are suspected of containing *Chlamydia* can also be tested using the method of the invention. Similarly, to test for HIV infection, the preferred sample is a blood sample.

5 The initial sample is treated to make DNA in the sample accessible for hybridization with the primers in the reaction mixture, for example by lysis, centrifugation to remove cell debris, and proteolytic digestion to expose the DNA. In accordance with the invention, it is not necessary to perform any type of preferential amplification of the target DNA in the sample prior to the use of the sample in the method of the invention, and indeed to reduce the number of steps and to simplify the assay it is preferred to use sample material which has not been previously  
10 subjected to any amplification procedure. As used in the specification and claims hereof, such sample materials in which the DNA in the sample has not been subjected to a preferential amplification step to increase one portion of the DNA relative to the remainder of the DNA will be referred to as "natural abundance samples." The term "natural abundance" does not, however, require the presence of all the DNA from the original sample. Thus, a sample  
15 containing just nuclear DNA, or just mitochondrial DNA or some subfraction of nuclear or mitochondrial DNA obtained by isolation from a microbial sample but not subjected to preferential amplification would be a "natural abundance" sample within the meaning of that term in the specification and claims of this application. The term "natural abundance" would also include a DNA sample prepared by conversion, for example by reverse transcription, of a  
20 total mRNA preparation or the genome of an RNA virus to cDNA; DNA isolated from an individual bacterial colony growing on a plate or from an enriched bacterial culture; and a viral DNA preparation where substantially the entire viral genome is isolated.

Primers used in the method of the present invention can be any pair of primers which hybridize with the sense and antisense strands DNA of the target microorganism flanking a  
25 selected region of diagnostic relevance, and which do not both hybridize to neighboring locations in human DNA or other microbial DNA potentially found in the sample. As used herein, the term "flanking" will be understood to mean the positioning of primers at the 5'-ends of the selected region on each DNA strand, such that extension of the primers leads to replication of the region between the primers. The primers are preferably selected such that the  
30 primer pair flanks a region that is about 500 bp or less, although primers spanning larger regions of DNA can be utilized with adjustments to the sequencing mixture (generally an increase in the

- 6 -

relative amount of deoxynucleotide triphosphates) to increase the amount of longer sequencing fragments produced.

Primers can be selected to hybridize with highly conserved regions which are the same in all variants of the target microorganism or can be prepared as degenerate primers to take known sequence variations at the primer site into account. Thus, the first and second primers of the invention may each be a discrete oligonucleotide species, or may be a set of oligonucleotide primers with similar but not identical sequences.

Primers can also be selected to bind to the sense and antisense strands of DNA flanking a region of the genome of the target microorganism which is constant across all known variants and forms of the microorganism, in which case the method of the invention would provide detection but not any specific qualitative characterization of the microorganisms, i.e., such primers could not provide discrimination between subspecies, serovars, strains, sub-types, biovars, variants, serotypes or between closely related species of the target microorganism. An example of such a primer pair is a primer pair that binds to the cryptic plasmid of *C. trachomatis* which is recognized as a suitably specific target sequence or detection purposes, but which is not known to vary from strain to strain. Preferably, however, the primers employed will flank a region of the target genome which is variable in sequence depending on the serotype of the organism. Thus, for *C. trachomatis* primers which flank portions of the *omp1* gene are preferred. Similarly, in the case of HIV detection, primers flanking known mutation sites in the HIV protease gene or reverse transcriptase gene produce fragments which permit both detection of HIV and the identification of the HIV variant present in the sample. Primers MY09 and MY11 (See example 10) give sequence information for most relevant types of human papilloma virus (HPV) but not other viruses.

In an alternative embodiment, primer pairs are selected which, when treated under the conditions of the invention, give sequence information from a much wider variety of organisms. This is the case with eubacterial "universal" primers such as 91E and 13B listed in Appendix I which can be used to obtain sequence data from the 16S rDNA gene of many bacteria. These primers are useful for identifying which bacterium is present in a septic blood culture, or any other pure but unknown culture. Patient samples which contain a broad range of bacteria will give a complex result, consisting of many overlapping sequences when tested with these primers. The complex result may, in some cases, provide useful information about the bacteria present.



- 7 -

However, in the normal course, it is advantageous to separate out the species, i.e. by plating them out first. In this case, individual pure colonies can be selected and identified.

In still another embodiment, the primer pairs are selected to determine whether a specific gene is present in the patient sample. The gene can be a toxin gene, a virulence gene, an anti-biotic resistance gene or a specific mutation which confers drug resistance or the like. Such a test can determine if a micro-organism is present and if it carries the gene at the same time.

Primers for other microorganisms can be derived from known sequence information. Appendix I lists a collection of suitable primer pairs for various other microorganisms which are taken from Persing et al., *supra*.

One or both of the primers may be labeled with a detectable label at the 5'-end thereof, particularly a fluorescent label such as fluorescein or a cyanine dye such as Cy 5.5. If labels are used on both primers, the labels selected should be spectroscopically-distinct, i.e., they should have either a different excitation spectrum or a different emission spectrum such that one primer can be distinguished from the other. When both primers are labeled with different detectable labels, the sequence of both strands of the sample can be determined in a single reaction.

The nucleotide triphosphate feedstock mixture is a standard mixture of the four conventional bases (A, C, G and T) in a buffer suitable for template-dependent primer extension with the enzyme employed. As will be appreciated by persons skilled in the art, the specific concentrations of the nucleotide triphosphates and the nature of the buffer will vary depending on the enzyme employed. Standard buffers and reagent concentrations for various known polymerase enzymes may be employed in the invention.

The reaction mixture used in the present invention also includes at least one type of chain-terminating nucleotide triphosphate. Separate reactions for the four different types of bases may be run either concurrently or successively. Running all four bases concurrently comports with conventional sequencing practice. However, a preferred embodiment of the present invention combines the single vessel methodology of this application with "single track sequencing" which is described in commonly assigned US Patent Application No. 08/577,858. In single track sequencing, the determination of the positions of only one (or in any event less than 4) nucleotide(s) of a target sequence is frequently sufficient to establish the presence of and determine the qualitative nature of a target microorganism by providing a finger-print or bar-code of the target sequence that may be sufficient to distinguish it from all other known varieties

- 8 -

of the sequence. Throughput is increased by reducing the number of reactions and electrophoresis runs required to identify a sequence. By selection of the order of bases tested, and intermediate analysis, it may be unnecessary to run all four bases to determine the presence and specific qualitative nature of any target microorganism present in the sample.

5       The polymerase enzyme used in the invention is a thermostable polymerase enzyme which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of deoxynucleotides. ThermoSequenase™ is exemplary of such an enzyme. Reeve et al., *Nature* 376: 796-797 (1995). Tabor et al. have also described enzymes which have increased processivity and increased levels of incorporation of  
10       dideoxynucleotides. (See EP-A1-0 655 506, which is incorporated herein by reference) Roche sells an enzyme under the trademark TAQ-FS which meets these criteria as well.

      The absolute and relative amounts of nucleotide triphosphates and chain-terminating nucleotide triphosphates may be optimized for the particular enzyme employed. In general, however, the nucleotide triphosphates will be included at in the reaction mixture at concentra-  
15       tions of from 250  $\mu$ M to 1.5 mM, and the chain-terminating nucleotide triphosphate will be included at a level of from 0.5  $\mu$ M to 30  $\mu$ M to produce compositions in which the mole ratio of the chain terminating nucleotide triphosphate to the corresponding nucleotide triphosphate is from 1:50 to 1:1000, preferably from 1:100 to 1:500. This will result in incorporation of a chain-terminating nucleotide triphosphate into from 30 to 100 percent of the extending polymer chains  
20       formed during the thermal cycling of the reaction mixture.

      The basic method of the invention can also be enhanced by various modifications without departing from the scope of the present invention. For example, improvements in reproducibility and sensitivity can be obtained by using a combination of an enzyme having a high affinity for incorporation of dideoxynucleotide triphosphates into the extending polymer,  
25       e.g., Thermo Sequenase™, and one having a low affinity for incorporation of dideoxynucleotide triphosphates into the extending polymer, e.g., Taq polymerase, under conditions where both enzymes are actively catalyzing template-dependent primer extension polymerization. As noted above, the high affinity enzyme produces almost entirely termination products, with very few of the polymers actually being extended to full length. On the other hand, the low affinity enzyme  
30       produces almost exclusively full length product, with relatively few termination products. Addition of the low affinity enzyme to the reaction mixture increases the sensitivity of the

- 9 -

method by producing more full length material to be sequenced without increasing the processing time or adding processing steps. The increase in sensitivity can be controlled by varying the ratio of high affinity to low affinity enzyme present in the mixture.

5 It will be noted, however, that including of low affinity enzyme to produce full length product will also result in the formation of a very intense labeled full-length product peak. This peak may make analysis of the bases near the end of the sequence difficult. To obtain the benefits of increased sensitivity while making less full length product, it may be desirable to utilize a low affinity enzyme which is more thermolabile than Taq polymerase, such that the low affinity enzyme is essentially inactivated by the end of the first 15 to 25 cycles. This would  
10 allow the production of longer fragments early in the assay and the generation of more terminated fragments late in the assay.

The reaction mixture of the invention may also incorporate other additives which enhance the formation of sequencing fragments. For example, a product called TaqStart™ Antibody is a monoclonal antibody which binds to and blocks the activities of Taq polymerase.  
15 This antibody is added to PCR reactions using Taq polymerase to block enzyme activity during set-up at ambient temperature to prevent or reduce the formation of non-specific amplification products. TaqStart™ Antibody can be used in the present invention with Thermo Sequenase™ to reduce nonspecific primer extension reactions.

Other materials which can be used in the reaction mixture of the invention are uracil-  
20 DNA glycosylases and corresponding unconventional nucleotides as described in US Patent No. 5,418,149, incorporated herein by reference, to reduce non-specific product formation. Roche sells a product under the trademark AMPERASE™ which can be used conveniently for this purpose.

The method of the invention is suitably practiced using a kit which provides the appropriate reagents in conveniently packaged form. To reduce the number of sample preparation steps,  
25 and thus to reduce the risk of erroneous results, such a kit will suitably include at least one pre-prepared mixture comprising all four nucleotide triphosphates and at least one chain terminating nucleotide triphosphate, where the mole ratio of chain terminating nucleotide to the corresponding deoxynucleotide triphosphate is from 1:50 to 1:1000, preferably 1:100 to 1:500.

30 The invention will now be further described by way of the following non-limiting examples.

- 10 -

EXAMPLE 1

The presence of the sexually transmitted disease pathogen *Chlamydia trachomatis* in a patient sample is detected according to the method of the invention as follows.

Urine samples from patients suspected of carrying a sexually transmitted disease pathogen are prepared for sequence-based diagnosis as follows. 100 ul of first void urine are deposited in a sterile microcentrifuge tube. The tube is centrifuged at 12,000 x g for 20 min; the supernatant is removed. 100 ul of Lysis Solution (Proteinase K @ 100 g/ml; 1% Tween 20) is added to the bacterial pellet and incubated 1 h at 55°C, or 18 h at room temperature. After a final incubation at 95°C for 10 minutes, 200 ul of Geneclean II glass milk is added, according to the manufacturer's instructions. (Bio 101, Inc) DNA is eluted in 10 ul of double distilled H<sub>2</sub>O. (A lysis solution control may be prepared if desired, by adding the lysis solution to a sterile tube (a tube without any urine pellet), and treating this tube like the others.)

The sample natural abundance DNA is then treated according to the method of the invention with a pair of primers and reagents to identify the sequence of a *C. trachomatis* gene present in the sample, if any. A suitable *C. trachomatis* specific target for sequencing is the cryptic plasmid. Primers that may be used are

Name	Sequence	
KL1:	TCCGGAGCGA GTTACGAAGA	[SEQ ID NO: 1]
KL2:	ATTCAATGCC CGGGATTGGT	[SEQ ID NO: 2]

These sequencing primers were employed previously for PCR amplification reactions, but not sequencing (Mahony et al., "Confirmatory polymerase chain reaction testing for *Chlamydia trachomatis* in first void urine from asymptomatic and symptomatic men" *J. Clin Microbiol.* 30:2241-2245 (1992)).

Either primer may be labeled at the 5'-end with a detectable label such as a Cy5.5 fluorophore. If both primers are labeled, they should be distinguishable. Labels are selected on the basis of the instrument employed for detection. Labeling reactions are performed according to methods well known in the art, such as amidite labeling or dye-ester condensation.

The sequencing reaction mixture is prepared by combining 2.5 ul of the prepared DNA sample, 0.67 ul of 10 uM primer KL1 (labeled with Cy5.5), 0.45 ul of KL2 primer at 10 uM, 2 ul of THERMOSEQUENASE reaction buffer (250 mM Tris-HCl pH 9.0 @ 25°C, 39 mM

- 11 -

MgCl<sub>2</sub>), 2 ul of THERMOSEQUENASE enzyme (Amersham Life Sciences) diluted 1/10 in the dilution buffer provided with the enzyme and 5.38 ul of double distilled H<sub>2</sub>O. The final volume is 13 ul.

3 ul of the sequencing reaction mixture is placed in each of 4 clean tubes and covered with one drop of mineral oil (Sigma Chemical Co., Cat # M-5904). The tube is placed in a PTC-100 thermal cycler (M.J. Research, Maine) and heated for 3 min at 94°C, then cooled to 85°C. One of the following termination mixtures are then added to each of the 4 tubes:

- 3 ul of dNTP:ddATP (1 mM each dNTP, 3.3 uM ddATP) in tube A.
- 3 ul of dNTP:ddCTP (1 mM each dNTP, 3.3 uM ddCTP) in tube C.
- 3 ul of dNTP:ddGTP (1 mM each dNTP, 3.3 uM ddGTP) in tube G.
- 3 ul of dNTP:ddTTP (1 mM each dNTP, 3.3 uM ddTTP) in tube T.

The dNTP:ddNTP mixes are preferably heated to 85°C when added to the tube. The reaction mixture is mixed well and it is subjected to the following thermal cycling regime for 55 cycles:

94°C/30 sec.

60°C/30 sec.

70°C/1 min

After the last cycle, the tubes are kept at 70°C for 2 min, then cooled to 4°C until ready for loading. To view the reaction products, 6 ul of loading buffer (dye/stop solution) is added to each tube. The aqueous phase (the bottom phase disposed under the oil layer) is removed and put it in another tube. The sample is heated to 75°C for 3 min, and put on ice. 2 ul of each sample is loaded in each well of a MicroGene Blaster automated DNA sequencer (Visible Genetics Inc., Toronto, ON). The reaction products are electrophoretically separated and detected. The data is analyzed using GeneObjects software (Visible Genetics Inc., Toronto, ON) to base-call (i.e. determine the DNA sequence) of the samples. The base-called sequence is compared to the known *C. trachomatis* sequence to confirm diagnosis. Results are reported to the patient file.

## EXAMPLE 2

The method of the invention may be employed to identify not only the presence of *C. trachomatis* in a patient sample but also the strain identity. Health care workers currently seek to

- 12 -

distinguish among *Chlamydia trachomatis* strains to determine the molecular epidemiologic association of a range of diseases with infecting genotype (See Dean, D. et al "Major Outer Membrane Protein Variants of *Chlamydia trachomatis* Are Associated with Severe Upper Genital Tract Infections and Histopathology in San Francisco." J. Infect. Dis. 172:1013-22 (1995)).

A suitable strain specific target for *C. trachomatis* is the *omp1* (outer membrane protein) gene which has at least 4 variable sequence ("VS") domains that may be used to distinguish among the 15 known genotypes of *C. trachomatis* (Yuan, Y et al. "Nucleotide and Deduced Amino Acid Sequences for the Four Variable Domains of the Major Outer Membrane Proteins of the 15 *Chlamydia trachomatis* Serovars" Infect. Immun. 57 1040-1049 (1989)).

Strain identification is achieved using the method of Example 1 with the following modifications. First of all, because of the length of the VS domains, separate reactions are performed to obtain sequence from VS1/VS2 and VS3/VS4. The following oligonucleotide primers may be employed:

For VS1/VS2:

Name	Sequence	
MF21	CCGACCGCGT CTTGAAAACA GATGT	[SEQ. ID NO. 3]
MB22	CACCCACATT CCCAGAGAGC T	[SEQ. ID NO. 4]

For VS3/VS4

Name	Sequence	
MVF3	CGTGCAGCTT TGTGGGAATG T	[SEQ. ID NO. 5]
MB4	CTAGATTTC A TCTTGTTCAA TTGC	[SEQ. ID NO. 6]

These sequencing primers were employed previously for PCR amplification reactions, but not sequencing. Mahoney et al., *supra*.

These oligonucleotide primers are used in separate reactions in place of KL1 and KL2 in Example 1. The sample preparation and sequencing reactions are performed as in Example 1. The reaction products are electrophoretically separated and detected on a MicroGene Blaster automated DNA sequencing apparatus (Visible Genetics Inc., Toronto, ON). The data is analyzed using GeneObjects software to base-call the samples and to compare the data to the known varieties of *C. trachomatis*. Pure populations generally give unambiguous sequence data. Where heterozygous mixed populations are detected, a circumstance thought to occur in 1-3% of

- 13 -

clinical *C. trachomatis* samples, the software identifies the strains which could be combined to result in the particular heterozygote sample detected.

### EXAMPLE 3

5 Strain-specific *C. trachomatis* identification over the VS1/VS2 domain can be achieved according to the method in Example 1, by using the following degenerate primers sets:

Forward

OMP291: AGCATGCGTR TKGTTACTA YGG [SEQ ID NO. 7]  
(labeled with Cy5.5). Base 175 to 197 of the ORF of the omp1 gene of *C. trachomatis*.

10 Forward

OMP314A: TGACTTTGTT TTCGACCGYG TTTT [SEQ ID NO. 8]  
(labeled with Cy5.5). Base 198 to 221 of the ORF of the omp1 gene of *C. trachomatis*.

Reverse

OMP722: CTAAAGTYGC RCATCCACAT TCC [SEQ ID NO. 9]  
15 Base 637 to 615 of the ORF of the omp1 (in serovar K) gene of *C. trachomatis*. The primer may not have the exact same sequence as in serovar K.

Reverse

OMP711: CATCCACATT CCCASARAGC TGC [SEQ ID NO. 10]  
20 Base 626 to 604 of the ORF of the omp1 (in serovar K) gene of *C. trachomatis*. The primer may not have the exact same sequence as in serovar K.

These primers sets are preferably used in the following combinations:

- (1) OMP291-OMP722, sequencing a 455 to 463-bp (depending on the serotype) fragment of the omp1 gene of *C. trachomatis*; or
- 25 (2) OMP314A-OMP711, sequencing a 421 to 430-bp (depending on the serotype) fragment of the omp1 gene of *C. trachomatis*.

### EXAMPLE 4

30 The method as exemplified in Examples 1, 2 and 3 may be further improved by employing different labels, preferably fluorescent labels, on the different primers for use in a multi-dye sequencer. This method takes advantage of the fact that a given termination mixture

- 14 -

containing, for example, ddATP will give chain termination products for the A nucleotide in both directions. The different primer labels means that one reaction mixture loaded in a single lane of an automated DNA sequencing apparatus designed to detect the two labels (a "multi-dye sequencer") will identify the A nucleotide of both sense and antisense strands. Separate  
5 reactions are performed for the other 3 nucleotides. Using only 4 lanes of an electrophoresis gel, and 4 reaction mixtures, the DNA sequences of both the sense and anti-sense strands can be obtained. This information allows the operator to resolve any ambiguities that may be present.

Use of two different labels lends itself to a further improvement. As noted above, in a reaction according to the invention, the results of the ddATP reaction will give chain termination  
10 products for the A nucleotide in both directions. Since the A nucleotide in one direction corresponds to the T nucleotide in the other, a single reaction can provide the location of two bases. A second termination reaction with, for example, ddCTP will then obtain the positions of the other two nucleotides, C and G. Thus only two lanes of an electrophoresis gel and 2 reaction mixtures are required to identify the location of all 4 bases of the sequence.

A suitable multi-dye sequencer for use with this aspect of the invention, is the Applied Biosystems 377 Prism automated DNA sequencer (Applied Biosystems Inc., Foster City, CA). The fluorescent labels are selected to be detectable on the 377 instrument. Instead of the dye-terminator chemistry suggested in the Applied Biosystems product literature, however, the fluorescent labels must be conjugated to the 5' end of the primer molecules. The samples are  
20 electrophoresed, detected and the detected data is recorded.

Sophisticated software such as GeneObjects software (Visible Genetics Inc, Toronto, CA) may be used to assist in evaluation of the results. This software may employ the methods of commonly assigned US Patent Applications Nos. 08/497,202 and 08/670,534 and International Patent Application No. PCT/US96/11130, all of which are incorporated herein by reference. In  
25 one of the methods, the single nucleotide data tracks are evaluated and nucleotides are positioned relative to the known (or standard) DNA sequence expected from the sample. When data tracks are generated for each of the four nucleotides, the full DNA sequence of the sample may be base-called. The base-called sequence is then compared to the library of known sequences to determine which *C. trachomatis* strain or strains are present in the sample.



- 15 -

EXAMPLE 5

The sequence of both the sense strand and antisense strand of a *C. trachomatis* cryptic plasmid gene may be obtained in a one step reaction using the primers:

Name	Sequence	
5 KL1:	TCCGGAGCGA GTTACGAAGA	[SEQ ID NO. 1]
CT1590:	ATGCCCGGGA TTGGTTGATC	[SEQ ID NO. 11]

Combine the following materials and mix well:

	Concentration	Amount
10 Patient Sample DNA		11.25 ul
KL1*Cy5.5 Primer	10 uM 3	ul
CT1590*Fluoresceine Primer	10 uM 2	ul
Enzyme Diluent (Amersham plc)		8 ul
ThermoSequenase Enzyme	32 U/ul	0.9 ul
15 double distilled H <sub>2</sub> O	24.2	ul

Take 11 ul of the mixture and add 2 ul of 13X buffer [Tris-HCl 260 mM pH 8.3, MgCl<sub>2</sub> 39 mM] (final concentration 20 mM Tris-HCl pH 8.3, 3 mM MgCl<sub>2</sub>). Mix well and place 3 ul into each of 4 tubes. Heat tube to 94°C for 5 mins then reduce temperature to 85°C. Add and mix 3 ul of an 85 C dNTP/ddNTP solution consisting of 0.75 mM each dNTP and 2.5 uM of a chain terminating nucleotide triphosphate (ddNTP) (use a different ddNTP in each of the 4 tubes).

Treat the mixture to 60 cycles of the following thermal cycling reactions: 94°C for 10 sec, 62°C for 15 sec, 70°C for 1 min. Upon completion, treat the mixture for a final 5 min at 70°C and then store at 4°C until ready for loading. For viewing the reaction products, add an equal volume of stop/loading solution (95% formamide plus a colored dye). Take 1.5 ul and load in a single lane of a MicroGene Blaster automated DNA sequencer (Visible Genetics Inc., Toronto). Load the remaining mixture (@ 10.5 ul) in a single lane of an ALF Automated Sequencer (Pharmacia LKB, Uppsala, Sweden). The reaction products from the Cy5.5 labeled primer are detected on the MicroGene Blaster using GeneObjects Software. The reaction products from the fluorescein labeled primer are detected on the ALF Automated Sequencer using GeneObjects

- 16 -

Software. The base-calling results of the Cy5.5 labeled primer were compared to the known sequence of the gene by the GeneLibrarian component of GeneObjects.

#### EXAMPLE 6

5 As described in U.S. Patent Application Serial No. 08/577,858, not all 4 nucleotides of *C. trachomatis*, or any polymorphic or multiple allelic locus of any gene or organism necessarily need to be determined in order to ascertain which allele or variant is present. In many cases, positioning less than four nucleotides may be sufficient to determine with certainty which allele is present. The method of Examples 1- 4 may be modified to obtain single nucleotide data tracks  
10 (or fragment patterns) by performing only one of the termination reactions at a time.

In the case of detection and serotyping of *C. trachomatis*, the evaluation of the A track alone over the first 100 nucleotides of the *omp1* gene, aligning to nucleotides 249-349 of the serovars C and K, can distinguish the serovars. Appendix II is a text file representation of the *omp1* gene in each of the serovars. The sequences are all aligned to the last (3') nucleotide of the  
15 detectably labeled primer omp314A. (Appendix II shows sequences starting 29 bp downstream of the 3'-nucleotide.) This illustration differs from a traditional "consensus" sequence illustrations in that all missing bases (usually represented by N's or raised dashes) are deleted. The A's are illustrated in the order and positions in which they would be expected to appear after a sequencing reaction and upon detection by an automated DNA electrophoresis apparatus.

20 If, in another microorganism, the A lane (or other preferred first lane) were not sufficient to distinguish all types, a second reaction for the C, G or T nucleotide could be performed to further define the qualitative nature of any target microorganism present in the sample. Because the sequences of the types are previously known, the operator can determine which of the nucleotides provide the greatest information and will analyze those nucleotides first.

#### EXAMPLE 7

The presence of and strain identity of *C. trachomatis* in a patient sample may be determined according to the methods of the previous examples by substituting the following  
30 primer pairs. These primers are used to determine the sequence of the *omp1* gene (publicly available at DNASIS Accession No. X62921).

Forward Primer (5' Primer) labeled with a detectable label such as Cy5.5:

- 17 -

Primer OMP312: GGAGACTTTG TTTTCGACCG [SEQ ID NO 12]

Position 312-331 of X62921

and one of the following Reverse Primers (3' Primer) (optionally labeled with a detectable label different from the 5' primer):

5 Primer OMP708: CATTCCCACA AAGCTGCGCG [SEQ ID NO 13]

Position 727-708 of X62921

Primer OMP706: TTCCCACAAA GCTGCGCGAG [SEQ ID NO 14]

Position 725-706 of X62921

Primer OMP704: CCCACAAAGC TCGCGAGCG [SEQ ID NO 15]

10 Position 723-704 of X62921

The following combination can be used to obtain DNA sequence over the following maximum lengths:

OMP312-OMP708: 416-nt region of omp1

OMP312-OMP706: 414-nt region of omp1

15 OMP312-OMP704: 412-nt region of omp1

### EXAMPLE 8

The presence of and strain identity of *C. trachomatis* in a patient sample may be determined according to the method of previous examples, using *C. trachomatis* ribosomal DNA (rDNA) specific primers such as

20 CT220 ACCTTTCGGT TGAGGGAGAG TCTA [SEQ ID NO 16]

and

CT447 GGACCAATTC TTATTCCCAA GCGA [SEQ ID NO 17]

25 Haydock et al., Chap 1.10 in Persing et al., *supra*.

### EXAMPLE 9

The sequence of both the sense strand and antisense strand of the protease gene of HIV-1 integrated into natural abundance DNA of lymphocytes may be obtained in a one step reaction as

30 follows.

- 18 -

Natural abundance DNA is prepared from the patient blood lymphocyte sample according to a standard method such as a standard salting-out procedure (as provided by the Puregene DNA Isolation Kit, Gentra Systems, Inc., Minneapolis) or by detergent and proteinase K treatment (Current Protocols in Molecular Biology, Eds. Ausubel, F.M. et al, (John Wiley & Sons; 1995)).

Combine the following materials and mix well:

		Concentration		Amount
Patient Sample DNA			11.25	ul
PR211F*Cy5.5 Primer		10 uM	3	ul
10	or			
PR281*Cy5.5 Primer		10 uM	3	ul
PR526*Fluorescein Primer		10 uM	2	ul
Enzyme Diluent (Amersham plc)			8	ul
15	THERMOSEQUENASE Enzyme	32 U/ul	0.9	ul
double distilled H2O			24.2	ul

The primers have the following sequences:

Name	Sequence	
20	Choice of Forward Primers	
PR211F	ATCACTCTTT GGCAACGACC	[SEQ ID No. 18]
	(Forward), base 6 to 25 of the protease gene	
PR281	CAGGAGCAGA TGATACAGTA TTAG	[SEQ ID No. 19]
	(Forward), base 76 to 99 of the protease gene	
25	Reverse Primer	
PR526:	CCATTCCTGG CTTTAATTTT ACTGG	[SEQ ID No. 20]
	(Reverse), bases 321 to 345 of the protease gene.	

PR211F-PR526 creates a sequencing fragment of maximum size 340 bp. PR281-PR526 creates a sequencing fragment of maximum size 270 bp. Both regions contain the sequence of the various codons where mutations are involved in protease inhibitor resistance (Codons 46, 48, 54, 63 82 84 and 90).

- 19 -

Take 11 ul of the mixture and add 2 ul of 13X buffer [Tris-HCl 260 mM pH 8.3, MgCl<sub>2</sub> 39 mM] (final concentration 20 mM Tris-HCl pH 8.3, 3 mM MgCl<sub>2</sub>). Mix well and place 3 ul into each of 4 tubes. Heat tube to 94 C for 5 mins then reduce temperature to 85 C. Add and mix 3 ul of an 85 C dNTP/ddNTP solution consisting of 0.75 mM each dNTP and 2.5 uM of a chain terminating nucleotide triphosphate (ddNTP) (use a different ddNTP in each of the 4 tubes).

Treat the mixture to 60 cycles of the following thermal cycling reactions: 94 C for 10 sec, 62 C for 15 sec, 70 C for 1 min. Upon completion, treat the mixture for a final 5 min at 70 C and then store at 4 C until ready for loading. For viewing the reaction products, add an equal volume of stop/loading solution (95% formamide plus a coloured dye). Take 1.5 ul and load in a single lane of a MicroGene Blaster automated DNA sequencer (Visible Genetics Inc., Toronto). Load the remaining mixture (@ 10.5 ul) in a single lane of an ALF Automated Sequencer (Pharmacia LKB, Uppsala, Sweden). The reaction products from the Cy5.5 labeled primer are detected on the MicroGene Blaster using GeneObjects Software. The reaction products from the fluorescein labeled primer are detected on the ALF Automated Sequencer using GeneObjects Software. The base-called results from each primer were compared to the known sequences of HIV-1 by GeneLibrarian (a component of GeneObjects (Visible Genetics Inc, Toronto).

#### EXAMPLE 10

The presence and type of human papilloma virus (HPV) present in a patient sample can be determined according to the method of the invention by following the protocol in Example 1 with the following modifications.

Patient sample DNA is extracted from 250 ul urine specimens using GeneClean II (Bio 101, Inc.). The sample is then treated as described previously but employing the degenerate primer pair:

Forward Primer: MY11

GCMCAGGGWC ATAAYAATGG

[SEQ ID No. 21]

Reverse Primer: MY09

CGTCCMAARG GAWACTGATC

[SEQ ID No. 22]

- 20 -

The reactions are performed as before, using ThermoSequenase enzyme or the like. Reaction products are detected on an automated electrophoresis/detection device such as the MicroGene Blaster. The sequence is analyzed and compared to the known varieties of HPV to identify the type. The result is reported to the patient file.

- 21 -

APPENDIX I

Suitable Sequencing Primer Pairs for Identification and  
Sub-Typing of Infectious Pathogens  
cf. Diagnostic Molecular Microbiology (Eds. Persing et al.)  
(1993; American Society for Microbiology; Washington D.C.)

## Bacterial Pathogens Universal (16S rDNA) Typing Primers

Pathogen Name: Universal Bacterial Identification  
Gene: 16s rDNA

Forward Primer: 91E  
TCAAAGGAAT TGACGGGGGC [SEQ ID No. 23]  
Site of Specific Hybridization: nt 911-930  
Reverse Primer: 13B  
AGGCCCGGGA ACGTATTCAC [SEQ ID No. 24]  
Site of Specific Hybridization: nt 1390-1371  
Maximum fragment size: 475 nt

Pathogen Name: Universal Bacterial Identification  
Gene: 16s rDNA

Forward Primer: 515FPL  
TGCCAGCAGC CGCGGTAA [SEQ ID No. 25]  
Site of Specific Hybridization: nt 515-533  
Reverse Primer: 806R  
GGACTACCAG GGTATCTAAT [SEQ ID No. 26]  
Site of Specific Hybridization: nt 806-787  
Maximum fragment size: 328 nt

Pathogen Name: Universal Bacterial Identification  
Gene: 16s rDNA

Forward Primer: 11E  
GAGGAAGGTG GGGATGACGT [SEQ ID No. 27]  
Site of Specific Hybridization: nt 1175-1194  
Reverse Primer: 13B  
AGGCCCGGGA ACGTATTCAC [SEQ ID No. 28]  
Site of Specific Hybridization: nt 1390-1371  
Maximum fragment size: 233 nt

Pathogen Name: Eubacterial Typing (Broad range of eubacteria)  
Gene: 16S rDNA

Forward Primer :285  
GAGAGTTTGA TCCTGGCTCA G [SEQ ID No. 29]  
Site of Specific Hybridization: nt 9-30  
Reverse Primer: 244  
CCCACTGCTG CCTCCCGTAG [SEQ ID No. 30]  
Site of Specific Hybridization: nt 341-361  
Maximum fragment size: 352 bp

## Bacteria

Pathogen Name: Mycobacteria Typing ( M. tuberculosis complex)  
Gene: 16S rDNA

Forward Primer:285  
GAGAGTTTGA TCCTGGCTCA G [SEQ ID No. 31]  
Site of Specific Hybridization: nt 9-30  
Reverse Primer:259

- 22 -

TTTCACGAAC AACGCGACAA [SEQ ID No. 32]  
Site of Specific Hybridization: nt 590-609  
Maximum fragment size: 600 bp

Pathogen Name: Mycobacterium tuberculosis  
Gene: IS6110  
Forward Primer:T5  
CTCGTCCAGC GCCGCTTCGG [SEQ ID No. 33]  
Site of Specific Hybridization: nt 758-788  
Reverse Primer:T4  
CCTGCGAGCG TAGGCGTCGG [SEQ ID No. 34]  
Site of Specific Hybridization: nt 881-862  
Maximum fragment size: 123 bp

Pathogen Name: Rickettsia rickettsii (Rocky Mountain spotted fever)  
Gene: 17 K Da Ag Gene  
Forward Primer:TZ15  
TTCTCAATTC GGTAAGGC [SEQ ID No. 35]  
Site of Specific Hybridization: nt 191-209  
Reverse Primer :TZ16  
ATATTGACCA GTGCTATTTC [SEQ ID No. 36]  
Site of Specific Hybridization: nt 437-419  
Maximum fragment size: 247 bp

Pathogen Name: Ehrlichia chaffeensis  
Gene: 16s rDNA  
Forward Primer: HE1  
CAATTGCTTA TAACCTTTTG GTTATAAAT [SEQ ID No. 37]  
Site of Specific Hybridization: nt 49-77  
Reverse Primer:HE3  
TATAGGTACC GTCATTATCT TCCCTAT [SEQ ID No. 38]  
Site of Specific Hybridization: nt 438-412  
Maximum fragment size: 390 bp

Pathogen Name: Borrelia burgdorferi (Lyme disease)  
Gene: Outer Surface Protein A  
Forward Primer:OSPA149  
TTATGAAAAA ATATTTATTG GGAAT [SEQ ID No. 39]  
Site of Specific Hybridization: nt 1  
Reverse Primer: OSPA319  
CTTTAAGCTC AAGCTTGTCT ACTGT [SEQ ID No. 40]  
Site of Specific Hybridization: nt 193  
Maximum fragment size: 193 bp

Pathogen Name: Borrelia burgdorferi (Lyme disease)  
Gene: Outer Surface Protein A  
Forward Primer:OSPA4  
CTGCAGCTTG GAATTCAGGC ACTTC [SEQ ID No. 41]  
Site of Specific Hybridization: nt 638  
Reverse Primer : OSPA2  
GTTTGTGAAT TTCAACTGCT GACC [SEQ ID No. 42]  
Site of Specific Hybridization: nt 793  
Maximum fragment size: 156 bp



- 23 -

Pathogen Name: *Borrelia burgdorferi* (Lyme disease)  
Gene: 16s rDNA  
Forward Primer: DD06  
ATCTGTTACC AGCATGTAAT [SEQ ID No. 43]  
Site of Specific Hybridization: nt 1105  
Reverse Primer: DD02  
CCCTCACTAA ACATACCT [SEQ ID No. 44]  
Site of Specific Hybridization: nt 1472  
Maximum fragment size: 368 bp

Pathogen Name: *Borrelia burgdorferi* (Lyme disease)  
Gene: Flagellin  
Forward Primer: FLA1  
GATGATGCTG CTGGCATGGG AGTTTCTGG [SEQ ID No. 45]  
Site of Specific Hybridization: nt 121  
Reverse Primer: FLA3  
CTGTCTGCAT CTGAATATGT GCCGTTACCT G [SEQ ID No. 46]  
Site of Specific Hybridization: nt 320  
Maximum fragment size: bp

Pathogen Name: *Yersinia pestis* (the bubonic plague)  
Gene: 9.5 kb pesticin plasmid  
Forward Primer: Yp1  
ATCTTACTTT CCGTGAGAAG [SEQ ID No. 47]  
Site of Specific Hybridization: nt 971-990  
Reverse Primer: Yp2  
CTTGATGTT GAGCTTCCTA [SEQ ID No. 48]  
Site of Specific Hybridization: nt 1450-1431  
Maximum fragment size: 478 bp

Pathogen Name: *Treponema pallidum* (venereal syphilis)  
Gene: 47-kDA gene  
Forward Primer: 47-3  
TTGTGGTAGA CACGGTGGGT AC [SEQ ID No. 49]  
Site of Specific Hybridization: nt 692 - 713  
Reverse Primer: 47-4  
TGATCGCTGA CAAGCTTAGG CT [SEQ ID No. 50]  
Site of Specific Hybridization: nt 1187-1166  
Maximum fragment size: 496 bp

Pathogen Name: *Treponema pallidum* (venereal syphilis)  
Gene: 16S rDNA  
Forward Primer: Tpr3  
CTCAGAGATG AGCCTGCGAC CATT [SEQ ID No. 51]  
Site of Specific Hybridization: nt 230  
Reverse Primer: TPr4  
GCATTCCCTC CCGTCCTCAT TCTTC [SEQ ID No. 52]  
Site of Specific Hybridization: nt 480  
Maximum fragment size: 251 bp

Pathogen Name: *Chlamydia trachomatis* (infection of mucosal surfaces)  
Gene: MOMP  
Forward Primer: CT.0005

- 24 -

GATAGCGAGC ACAAAGAGAG CTAA [SEQ ID No. 53]  
Site of Specific Hybridization: nt 67  
Reverse Primer: CT.06  
TTCACATCTG TTTGCAAAAC ACGGTCGAAA ACAAAG [SEQ ID No. 54]  
Site of Specific Hybridization: nt 347  
Maximum fragment size: 281 bp

Pathogen Name: Chlamydia pneumoniae (respiratory disease)  
Gene: 474bp PST fragment  
Forward Primer: HL-1  
GTTGTTCATG AAGGCCTACT [SEQ ID No. 55]  
Site of Specific Hybridization: nt 30-49  
Reverse Primer: HR-1  
TGCATAACCT ACGGTGTGTT [SEQ ID No. 56]  
Site of Specific Hybridization: nt 467-448  
Maximum fragment size: 438 bp

Pathogen Name: Mycoplasma pneumoniae (respiratory disease)  
Gene: genomic  
Forward Primer: MP5-1  
GAAGCTTATG GTACAGGTTG G [SEQ ID No. 57]  
Reverse Primer: MP5-2  
ATTACCATCC TTGTTGTAAG [SEQ ID No. 58]  
Maximum fragment size: 144 bp

Pathogen Name: Mycoplasma speciation (Universal Primers for 8  
most common Mycoplasma species)  
Gene: 16S rDNA  
Forward Primer: Primer A  
GGCGAATGGG TGAGTAACAC G [SEQ ID No. 59]  
Site of Specific Hybridization: nt 87  
Reverse Primer: Primer B  
CGGATAACGC TTGCGACCTA TG [SEQ ID No. 60]  
Site of Specific Hybridization: nt 550  
Maximum fragment size: 464 bp

Pathogen Name: Legionella pneumophila (wound infection,  
respiratory disease)  
Gene:  
Forward Primer: LEG1  
GCTATGAGGA ATCTCGCTG [SEQ ID No. 61]  
Reverse Primer: LEG2  
CTGGCTTCTT CCAGCTTCA [SEQ ID No. 62]  
Maximum fragment size: 800 bp

Pathogen Name: Legionella dumoffii (wound infection, respiratory  
disease)  
Gene:  
Forward Primer: LDBKS1  
ATACACGTGG TGGAGGTAC [SEQ ID No. 63]  
Reverse Primer: LDBKS2  
GCGGGCAATA TCTTGATC [SEQ ID No. 64]  
Maximum fragment size: 1000 bp

Pathogen Name: Mycoplasma fermentans

- 25 -

Gene: IS-like element  
Forward Primer:RW005  
GGTTATTCGA TTTCTAAATC GCCT [SEQ ID No. 65]  
Site of Specific Hybridization: nt 1116  
Reverse Primer:RW004  
GGACTATTGT CTAAACAATT TCCC [SEQ ID No. 66]  
Site of Specific Hybridization: nt 1321  
Maximum fragment size: 206 nt

Pathogen Name: Ehrlichia  
Gene: 16S rDNA  
Forward Primer: 8F  
AGTTTGATCA TGGCTCAG [SEQ ID No. 67]  
Site of Specific Hybridization: nt 32  
Reverse Primer:GA1UR  
GAGTTTGCCG GGACTTCTTC T [SEQ ID No. 68]  
Site of Specific Hybridization: nt (about 400)  
Maximum fragment size: (about 400 nt)

#### Viruses

Human Immunodeficiency Virus Type 1 (HIV-1)  
Gene: gag  
Forward Primer:SK462  
AGTTGGAGGA CATCAAGCAG CCATGCAAAT [SEQ ID No. 69]  
Site of Specific Hybridization:1366-1395: nt  
Reverse Primer:SK431  
TGCTATGTCA GTTCCCCTTG GTTCTCT [SEQ ID No. 70]  
Site of Specific Hybridization: nt 1507-1481  
Maximum fragment size: 142 nt

Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)  
Gene: POL  
Forward Primer:POL1  
CCCGGGCCCC CTGACTTGTC [SEQ ID No. 71]  
Site of Specific Hybridization: nt 2802-2821  
Reverse Primer:POL3  
GCTTTCCTG TCCCACAGCAG [SEQ ID No. 72]  
Site of Specific Hybridization: nt 2916-2936  
Maximum fragment size: 237 nt

Hepatitis B Virus (HBV)  
Gene: surface antigen  
Forward Primer:Primer 1  
CAAGGTATGT TGCCCGTTTG [SEQ ID No. 73]  
Site of Specific Hybridization: nt 329-348  
Reverse Primer:Primer 2  
AAAGCCCTGC GAACCACTGA [SEQ ID No. 74]  
Site of Specific Hybridization: nt 587-568  
Maximum fragment size: 259 nt

Hepatitis C Virus (HCV)  
Gene: 5'UT

- 26 -

Forward Primer:5PUT c1-a  
CCCAACACTA CTCGGCTAG [SEQ ID No. 75]  
Site of Specific Hybridization: nt -74--92  
Reverse Primer:5PUT 1-s  
AACTACTGTC TTCACGAGA AAGC [SEQ ID No. 76]  
Site of Specific Hybridization: nt -266--289  
Maximum fragment size: 216 nt

Herpes simplex virus (HSV)  
Gene: DNA polymerase gene  
Forward Primer:HSV-3  
TACATCGGCG TCATCTGCGG GG [SEQ ID No. 77]  
Site of Specific Hybridization: nt 2821-2842  
Reverse Primer:HSV-4  
CAGTTCGGCG GTGAGGACAA AG [SEQ ID No. 78]  
Site of Specific Hybridization: nt 3090-3111  
Maximum fragment size: 290 nt

Herpesvirus 6  
Gene:  
Forward Primer:H6-6  
AAGCTTGAC AATGCCAAAA AACAG [SEQ ID No. 79]  
Reverse Primer:H6-7  
CTCGAGTATG CCGAGACCCC TAATC [SEQ ID No. 80]  
Maximum fragment size: 223 nt

Herpesvirus 7  
Gene:  
Forward Primer:HV7  
TATCCCAGCT GTTTTCATAT AGTAAC [SEQ ID No. 81]  
Reverse Primer: HV8  
GCCTTGCGGT AGCACTAGAT TTTTTC [SEQ ID No. 82]  
Maximum fragment size: 186 nt

Epstein-Barr Virus  
Gene: EBNA2  
Forward Primer:E2p1  
AAGGATGCCT GGACACAAGA [SEQ ID No. 83]  
Site of Specific Hybridization: nt 1813-1833  
Reverse Primer:E2p2  
TGGTGCTGCT GGTGGTGGCA AT [SEQ ID No. 84]  
Site of Specific Hybridization: nt 2409-2388  
Maximum fragment size: 596 nt

Cytomegalovirus (CMV) (member of Herpesviridae)  
Gene: CMV IE gene  
Forward Primer:CMV1  
CCTAGTGTGG ATGACCTACG GGCCA [SEQ ID No. 85]  
Site of Specific Hybridization: nt 1234-1258  
Reverse Primer:CMV2  
CAGACACAGT GTCCTCCCGC TCCTC [SEQ ID No. 86]  
Site of Specific Hybridization: nt 1459-1483  
Maximum fragment size: 249 nt

Varicella-Zoster Virus (VZV) (for Chicken Pox)

- 27 -

- Gene: unique genomic fragment  
Forward Primer: VZ7  
ATGTCCGTAC AACATCAACT  
Site of Specific Hybridization: nt 3377-3396 [SEQ ID No. 87]  
Reverse Primer: VZ8  
CGATTTTCCA AGAGAGACGC  
Site of Specific Hybridization: nt 3643-3624 [SEQ ID No. 88]  
Maximum fragment size: 267 nt
- JC Virus (JCV) distinguishing from BK virus and simian virus 40  
Gene: T antigen  
Forward Primer: P5  
AGTCTTTAGG GTCTTCTACC  
Site of Specific Hybridization: nt 4255-4274 [SEQ ID No. 89]  
Reverse Primer: P6  
GGTGCCAACC TATGGAACAG  
Site of Specific Hybridization: nt 4427-4408 [SEQ ID No. 90]  
Maximum fragment size: 172 nt
- Parvovirus B19  
Gene: VP Protein  
Forward Primer: Z  
GGAACAGACT TAGAGCTTAT TC  
Site of Specific Hybridization: nt 2537 [SEQ ID No. 91]  
Reverse Primer: Y  
GCTTG TGTA GTCCTTCACTA G  
Site of Specific Hybridization: nt 2774 [SEQ ID No. 92]  
Maximum fragment size: 259 nt
- Influenza A (Orthomyxoviridae)  
Gene: hemagglutinin H2  
Forward Primer: AH2B  
CAATAGCTGG TTTTATAGAA  
Site of Specific Hybridization: nt 1077 [SEQ ID No. 93]  
Reverse Primer: AH2CII  
TTATCATACA GATTCTTGAC  
Site of Specific Hybridization: nt 1425 [SEQ ID No. 94]  
Maximum fragment size: 349 nt
- Influenza B (Orthomyxoviridae)  
Gene: Matrix Protein  
Forward Primer: BMPB  
GAAGGCAAAG CAGAACTAGC  
Site of Specific Hybridization: nt 79 [SEQ ID No. 95]  
Reverse Primer: BMPCII  
TGGCCTTCTG CTATTTCAAA  
Site of Specific Hybridization: nt 380 [SEQ ID No. 96]  
Maximum fragment size: 302 nt
- Influenza C (Orthomyxoviridae)  
Gene: hemagglutinin  
Forward Primer: CHAB  
GTGCAAACCTG CATCTTGTGG  
Site of Specific Hybridization: nt 705 [SEQ ID No. 97]  
Reverse Primer: CHACII

- 28 -

CTCATTCTT GATCTCCATG

[SEQ ID No. 98]

Site of Specific Hybridization: nt 1145

Maximum fragment size: 441 nt

Rotavirus

Gene: vp7

Forward Primer:A2

GGACCAAGAG AAAACGTAGC

[SEQ ID No. 99]

Site of Specific Hybridization: nt 805

Reverse Primer:A4

GGTCACATCA TACAATTCTA ATCTAAG

[SEQ ID No. 100]

Site of Specific Hybridization: nt 1062

Maximum fragment size: 257 nt

Human Adenovirus

Gene: Hexon gene

Forward Primer:A2H/pcr 4R

ATGACTTTTG AGGTGGATCC CATGGA

[SEQ ID No. 101]

Reverse Primer:A2H/pcr 1

GCCGAGAAGG GCGTGCGCAG GTA

[SEQ ID No. 102]

Maximum fragment size: 134 nt

Rubella Virus

Gene: 40S ssRNA

Forward Primer:Ru2

TGCTTTGCC CATGGGACCT CGAG

[SEQ ID No. 103]

Site of Specific Hybridization: nt 1990-2013

Reverse Primer:Ru3

GGCGAACACG CTCATCACGG T

[SEQ ID No. 104]

Site of Specific Hybridization: nt 2310-2290

Maximum fragment size: 321 nt

Human Enteroviruses

Gene: 5'NTR

Forward Primer:MD91

CCTCCGGCCC CTGAATGCCG CTAAT

[SEQ ID No. 105]

Site of Specific Hybridization: nt 444-468

Reverse Primer:MD90

ATTGTCACCA TAAGCAGCCA

[SEQ ID No. 106]

Site of Specific Hybridization: nt 577-596

Maximum fragment size: 154 nt

Genital Human Papillomavirus (HPV)

Gene: L1 gene

Forward Primer:MY11

GCMCAGGGWC ATAAYAATGG

[SEQ ID No. 107]

Site of Specific Hybridization: nt 6582

Reverse Primer:MY09

CGTCCMAARG GAWACTGATC

[SEQ ID No. 108]

Site of Specific Hybridization: nt 7033

Maximum fragment size: 450 nt

Hantavirus

Gene: M segment

Forward Primer:Har M 30+

- 29 -

CACTGAATAA GAGGATACAA GAATGG [SEQ ID No. 109]  
Site of Specific Hybridization: nt 30  
Reverse Primer: Har M 403-  
GGAGGAATAT TACATGTGCC TTT [SEQ ID No. 110]  
Site of Specific Hybridization: nt 403  
Maximum fragment size: 374 nt

## Fungi

Cryptococcus neoformans (Universal fungal primers)  
Gene:  
Forward Primer: ITS1  
TCCGTAGGTG AACCTGCGA [SEQ ID No. 111]  
Reverse Primer: ITS4  
TCCTCCGCTT ATTGATATGC [SEQ ID No. 112]  
Maximum fragment size: 600 nt

Pneumocystis carinii  
Gene: 5S rDNA  
Forward Primer: 5S Sense  
AGTTACGGCC ATACCTCAGA [SEQ ID No. 113]  
Reverse Primer: 5S Antisense  
AAAGCTACAG CACGTCGTAT [SEQ ID No. 114]  
Maximum fragment size: 120 nt

Fungal Pathogens (Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis Trichophyton rubrum)  
Gene: 18S rDNA  
Forward Primer: NS3  
GCAAGTCTGG TGCCAGCAGC C [SEQ ID No. 115]  
Site of Specific Hybridization: nt 551  
Reverse Primer: RDR116  
CCGTCAATTC CTTTATGTTT CAGCCTT [SEQ ID No. 116]  
Site of Specific Hybridization: nt 1149  
Maximum fragment size: 599 nt

## Protozoa

Trypanosoma cruzi  
Gene: kinetoplast  
Forward Primer: S35  
AAATAATGKA CGGGTGAGAT GCATGA [SEQ ID No. 117]  
Reverse Primer: S36  
GGGTTGATT GGGTTGGTG T [SEQ ID No. 118]  
Maximum fragment size: 330 nt

Leishmania species  
Gene: kinetoplast  
Forward Primer: 13A  
GTGGGGGAGG GGCGTTCT [SEQ ID No. 119]  
Reverse Primer: 13B  
ATTTTACACC AACCCCCAGT T [SEQ ID No. 120]  
Maximum fragment size: 120 nt

- 30 -

*Plasmodium* (genus specific)

Gene: Nuclear small subunit rDNA

Forward Primer: 566R

GGATAACTAC GGAAAAGCTG TAGC [SEQ ID No. 121]

or Forward Primer: 570R

CGACTTCTCC TTCCTTTAAA AGATAGG [SEQ ID No. 122]

Reverse Primer: 567R

GTTCAAGATT AATAATTGCA ATAATCTATC CC [SEQ ID No. 123]

Maximum fragment size: about 500 nt

*Entamoeba histolytica* (amoebic dysentery)

Gene: SSU rDNA

Forward Primer: Psp5

GGCCAATTCA TTCAATGAAT TGAG [SEQ ID No. 124]

Site of Specific Hybridization: nt 200

Reverse Primer: Psp3

CTCAGATCTA GAAACAATGC TTCTC [SEQ ID No. 125]

Site of Specific Hybridization: nt 1075

Maximum fragment size: 876 nt

*Babesia microti*

Gene: SS rDNA

Forward Primer: Bab1

CTTAGTATAA GCTTTTATAC AGC [SEQ ID No. 126]

Site of Specific Hybridization: nt 38-60

Reverse Primer: Bab4

ATAGGTCAGA AACTTGAATG ATACA [SEQ ID No. 127]

Site of Specific Hybridization: nt 251-275

Maximum fragment size: 238 nt

*Giardia lamblia*

Gene: 18S rDNA gene

Forward Primer: JW1

GCGCACCAGG AATGCTTGT [SEQ ID No. 128]

Site of Specific Hybridization: nt 1251-1270

Reverse Primer: JW2

TCACCTACGG ATACCTTGTT [SEQ ID No. 129]

Site of Specific Hybridization: nt 1433-1414

Maximum fragment size: 183 nt

Pathogen Name: *Cryptosporidium* oocyst detection

Gene: 18S rDNA

Forward Primer: CP1

CCGAGTTTGA TCCAAAAGT TACGAA [SEQ ID No. 130]

Reverse Primer: CP2

TAGCTCCTCA TATGCCTTAT TGAGTA [SEQ ID No. 131]

Maximum fragment size: 452 nt

Pathogen Name: *Cyclospora* and *Eimeria* species

Gene: 18S rDNA

Forward Primer: CYC3FE

GGAATTCCTT CCGAGCTTCG CTGCGT [SEQ ID No. 132]

Site of Specific Hybridization: nt 685-704

Reverse Primer: CYC4RB

CGGGATCCCG TCTTCAAACC CCCTACTG [SEQ ID No. 133]



- 31 -

Site of Specific Hybridization: nt 978-959  
Maximum fragment size: 294 nt

#### Identification of Bacterial Toxin Genes

Pathogen Name: *Vibrio cholerae* 01 containing cholera toxin gene (epidemic cholera)

Gene: CTXA

Forward Primer: CTX2

CGGGCAGATT CTAGACCTCC TG

[SEQ ID No. 134]

Site of Specific Hybridization: nt 73-94

Reverse Primer: CTX3

CGATGATCTT GGAGCATTCC CAC

[SEQ ID No. 135]

Site of Specific Hybridization: nt 614-636

Maximum fragment size: 564 bp

Pathogen Name: Enterotoxigenic *Escherichia coli*

Gene: ST1a or ST1b

Forward Primer: ST1-1

TTAATAGCAC CCGGTACAAG CAGG

[SEQ ID No. 136]

Site of Specific Hybridization: nt 243-266

Reverse Primer: ST1-2

CTTGACTCTT CAAAAGAGAA AATTAC

[SEQ ID No. 137]

Site of Specific Hybridization: nt 127-144

Maximum fragment size: 147 bp

Pathogen Name: Enterotoxigenic *Escherichia coli*

Gene: LT1a or LT1b

Forward Primer: LT1a/b-1

TCTCTATRTG CAYACGGAGC

[SEQ ID No. 138]

Site of Specific Hybridization: nt 46-65

Reverse Primer: LT1-2

CCATACTGAT TGCCGCAAT

[SEQ ID No. 139]

Site of Specific Hybridization: nt 349-367

Maximum fragment size: 322 bp

Pathogen Name: Enterotoxigenic *Escherichia coli*

Gene: SLTII

Forward Primer: SLTII-1

CTTCGGTATC CTATTCCCGG

[SEQ ID No. 140]

Site of Specific Hybridization: nt 288-307

Reverse Primer: SLTII-2

GGATGCATCT CTGGTCATTG

[SEQ ID No. 141]

Site of Specific Hybridization: nt 747-766

Maximum fragment size: 478 bp

Pathogen Name: *Shigella* species and enteroinvasive *E. coli* (diarrheal disease)

Gene: Invasion plasmid ial locus

Forward Primer: Sh-1

CTGGATGGTA TGGTGAGG

[SEQ ID No. 142]

Reverse Primer: Sh-2

GGAGGCCAAC AATTATTTC

[SEQ ID No. 143]

Maximum fragment size: 320 bp

- 32 -

Pathogen Name: *Helicobacter pylori* (formerly *Campylobacter pylori*)

Gene: genomic

Forward Primer: CAM-2

TAACAAACCG ATAATGGCGC

[SEQ ID No. 144]

Reverse Primer: CAM-4

CATCTTGTTA GAGGGATTGG

[SEQ ID No. 145]

Maximum fragment size: 203 bp

Pathogen Name: *Toxigenic Clostridium difficile*

Gene: rDNA

Forward Primer: PG-48

CTCTTGAAAC TGGGAGACTT GA

[SEQ ID No. 146]

Reverse Primer: B

CCGTCAATTC MTTTRAGTTT

[SEQ ID No. 147]

Maximum fragment size: 291 bp

Pathogen Name: *Toxigenic Clostridium difficile*

Gene: Toxin B

Forward Primer: YT-17

GGTGGAGCTT CAATTGGAGA G

[SEQ ID No. 148]

Reverse Primer: YT-18

GTGTAAACCTA CTTTCATAAC ACCAG

[SEQ ID No. 149]

Maximum fragment size: 399 bp

Pathogen Name: *Staphylococcus aureus* toxins and virulence factors

Gene: sea

Forward Primer:SEA1

TTGGAAACGG TTAACGAA

[SEQ ID No. 150]

Site of Specific Hybridization: nt 490-509

Reverse Primer:SEA2

GAACCTCCC ATCAAAAACA

[SEQ ID No. 151]

Site of Specific Hybridization: nt 610-591

Maximum fragment size: 120 bp

Pathogen Name: *Staphylococcus aureus* toxins and virulence factors

Gene: seb

Forward Primer:SEB1

TCGCATCAA CTGACAAACG

[SEQ ID No. 152]

Site of Specific Hybridization: nt 634-653

Reverse Primer:SEB2

GCAGGTACTC TATAAGTGCC

[SEQ ID No. 153]

Site of Specific Hybridization: nt 1110-1091

Maximum fragment size: 478 bp

Pathogen Name: *Staphylococcus aureus* toxins and virulence factors

Gene: sec

Forward Primer: SEC1

GACATAAAAG CTAGGAATTT

[SEQ ID No. 154]

Site of Specific Hybridization: nt 676-695

Reverse Primer:SEC2

- 33 -

AAATCGGATT AACATTATCC [SEQ ID No. 155]  
Site of Specific Hybridization: nt 932-913  
Maximum fragment size: 257 bp

Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: sed

Forward Primer: SED1

CTAGTTTGGT AATATCTCCT

[SEQ ID No. 156]

Site of Specific Hybridization: nt 354-373

Reverse Primer: SED2

TAATGCTATA TCTTATAGGG

[SEQ ID No. 157]

Site of Specific Hybridization: nt 671-652

Maximum fragment size: 317 bp

Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: see

Forward Primer: SEE1

TAGATAAAGT TAAAACAAGC

[SEQ ID No. 158]

Site of Specific Hybridization: nt 491-510

Reverse Primer: SEE2

TAACTTACCG TGGACCCTTC

[SEQ ID No. 159]

Site of Specific Hybridization: nt 659-640

Maximum fragment size: 170 bp

Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: tss

Forward Primer: TSST1

ATGGCAGCAT CAGCTTGATA

[SEQ ID No. 160]

Site of Specific Hybridization: nt 251-270

Reverse Primer: TSST2

TTTCCAATAA CCACCCGTTT

[SEQ ID No. 161]

Site of Specific Hybridization: nt 600-581

Maximum fragment size: 350 bp

Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: eta

Forward Primer: ETA1

CTAGTGCATT TGTATTCAA

[SEQ ID No. 162]

Site of Specific Hybridization: nt 374-393

Reverse Primer: ETA2

TGCATTGACA CCATAGTACT

[SEQ ID No. 163]

Site of Specific Hybridization: nt 492-473

Maximum fragment size: 119 bp

Pathogen Name: Staphylococcus aureus toxins and virulence factors

Gene: etb

Forward Primer: ETB1

ACGGCTATAT ACATTCAATT

[SEQ ID No. 164]

Site of Specific Hybridization: nt 51-70

Reverse Primer: ETB2

- 34 -

TCCATCGATA ATATACCTAA [SEQ ID No. 165]  
Site of Specific Hybridization: nt 250-231  
Maximum fragment size: 200 bp

Pathogen Name: Bacterial meningitis (Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumonia, S. agalactiae, Listeria monocytogenes, enteric bacteria, or Mycobacterium tuberculosis)

Gene: 16s rDNA

Forward Primer:RW01

AACTGGAGGA AGGTGGGGAT [SEQ ID No. 166]

Reverse Primer:DG74

AGGAGGTGAT CCAACCGCA [SEQ ID No. 167]

Maximum fragment size: 370 nt

Pathogen Name: Streptococcus pyogenes exotoxins (Streptococcal Toxic Shock Syndrome)

Gene: speC

Forward Primer:F

CCACCTTGAC TATTT [SEQ ID No. 168]

Reverse Primer:R

TTAATTAGGA GGTA [SEQ ID No. 169]

Maximum fragment size: 936 nt

#### Identification of Anti-Microbial Resistance Loci

Pathogen Name: Rifampin Resistance Mutations in Mycobacterium tuberculosis and M. leprae

Gene: rpoB

Forward Primer:rpoB105

CGTGGAGGCG ATCACACCGC AGACGT [SEQ ID No. 170]

Reverse Primer:rpoB293

AGTGCACGCG GTGCACGTCG CGGACCT [SEQ ID No. 171]

Maximum fragment size: 215 nt

Pathogen Name: Human Immunodeficiency Virus Drug Resistance

Gene: HIV Reverse Transcriptase

Forward Primer:A(35)

TTGGTTGCAC TTAAATTTT CCCATTAGTC CTATT [SEQ ID No. 172]

Reverse Primer:NE-1(35)

CCTACTAACT TCTGTATGTC ATTGACAGTC CAGCT [SEQ ID No. 173]

Maximum fragment size: 805 nt

Pathogen Name: erm Erythromycin Resistance Genes (in S. aureus, E. coli, or Bacillus sphaericus)

Gene: erm

Forward Primer:E1

GARATIGGII IIGGIAARGG ICA\* [SEQ ID No. 174]

Reverse Primer:E2

AAYTGRTTYT TIGTRAA\* [SEQ ID No. 175]

Maximum fragment size: 530 nt

\*I=inosine

Pathogen Name: Methicillin-Resistant Staphylococcus

- 35 -

Gene: mecA

Forward Primer:RSM 2647

AAAATCGATG GTAAAGGTTG GC

[SEQ ID No. 176]

Site of Specific Hybridization: nt 1282-1303

Reverse Primer: RSM 2648

AGTTCTGCAG TACCGGATTT GC

[SEQ ID No. 177]

Site of Specific Hybridization: nt 1814-1793

Maximum fragment size: 533 nt

Pathogen Name: Penicillinase-Producing *Neisseria gonorrhoeae*

Gene: TEM-1

Forward Primer:PPNG-L

AGTTATCTAC ACGACGG

[SEQ ID No. 178]

Reverse Primer:PPNG-R

GGCGTACTAT TCACTCT

[SEQ ID No. 179]

Maximum fragment size: 761 nt

Pathogen Name: Aminoglycoside-Modifying Enzymes

Gene: aacC1

Forward Primer:aacC1-1

ACCTACTCCC AACATCAGCC

[SEQ ID No. 180]

Reverse Primer:aacC1-2

ATATAGATCT CACTACGCGC

[SEQ ID No. 181]

Maximum fragment size: 169 nt

Pathogen Name: Extended Spectrum of Beta-lactamases

Gene: TEM-1

Forward Primer:Lag.Std.3

AGAGAATTAT GCAGTGC

[SEQ ID No. 182]

Site of Specific Hybridization: nt 560

Reverse Primer:Amp. Primer 2

GACAGTTACC AATGCTTAAT CA

[SEQ ID No. 183]

Site of Specific Hybridization: nt 1074

Maximum fragment size: 514 nt

Pathogen Name: Fluoroquinolone Resistance mutations in  
*Mycobacterium tuberculosis*

Gene: gyrA

Forward Primer:GyrA1

CAGCTACATC GACTATGCGA

[SEQ ID No. 184]

Site of Specific Hybridization: nt 78-97

Reverse Primer:GyrA2

GGGCTTCGGT GTACCTCAT

[SEQ ID No. 185]

Site of Specific Hybridization: nt 379-397

Maximum fragment size: 320 nt

Pathogen Name: Isoniazid Resistance of *Mycobacterium tuberculosis*

Gene: katG

Forward Primer:katG904

AGCTCGTATG GCACCGGAAC

[SEQ ID No. 186]

Site of Specific Hybridization: nt 904

Reverse Primer:katG1523

TTGACCTCCC ACCCGACTTG

[SEQ ID No. 187]

Site of Specific Hybridization: nt 1523

Maximum fragment size: 620 nt

- 36 -

Pathogen Name: Vancomycin resistant Enterococci

Gene: vanB

Forward Primer: VanB1

CATCGCCGTC CCCGAATTTC AAA

[SEQ ID No. 188]

Reverse Primer: VanB2

GATGCGGAAG ATACCGTGGC T

[SEQ ID No. 189]

Maximum fragment size: 297 nt

- 37 -

APPENDIX II

		10	20	30	40	50	
OMP-A-1	1	-A-----	-----A--A	--A--A--	A--A-----	AAAA--A--	50
OMP-A-3	1	-A-----	-----A--A	--A--A--	A--A-----	AAAA--A--	50
OMP-D-1	1	AA-----	AA--A-AA	--A--A--	AA-----	-----A--A	50
OMP-B-2	1	AA-----	AA--A-AA	--A--A--	AA-----	-----A--A	50
OMP-Ba-1	1	AA-----	AA--A-AA	--A--A--	AA-----	-----A--A	50
OMP-C	1	-A-----	-----A--A	--A--A--	A--A-----	AAAA--A--	50
OMP-D-1	1	-A-----	AA--A-AA	--A--A--	AA--A--	-----A--A	50
OMP-D-2	1	-A-----	AA--A-AA	--A--A--	AA--A--	-----A--A	50
OMP-Da	1	-A-----	AA--A-AA	--A--A--	AA--A--	-----A--A	50
OMP-E	1	AA-----	AA--A-AA	--A--A--	AA-----	-----AA--A	50
OMP-H	1	-A-----	-----A--A	--A--A--	A--A--A--	AAAA--A--	50
OMP-I	1	-A-----	-----A--A	--A--A--	A--A--A--	AAAA--A--	50
OMP-J	1	-A-----	-----A--A	--A--A--	A--A--A--	AAAA--A--	50
OMP-K	1	-A-----	-----A--A	--A--A--	A--A--A--	AAAA--A--	50
OMP-L1	1	AA-----	AA--A-AA	--A--A--	AA-----	-----A--A	50
OMP-L2-1	1	AA-----	AA--A-AA	--A--A--	AA-----	-----A--A	50
OMP-L2-3	1	AA-----	AA--A-AA	--A--A--	AA-----	-----A--A	50
OMP-L3	1	AA-----	AA--A-AA	--A--A--	AA-----	-----A--A	50
OMP-LGV	1	AA-----	AA--A-AA	--A--A--	AA-----	-----A--A	50
		60	70	80	90	100	
OMP-A-1	51	-A--A-AAA	-----	---AAA-----	--A--AA	A-A-A--AA	100
OMP-A-3	51	-A--A-AAA	-----	---AAA-----	--A--AA	A-A-A--AA	100
OMP-D-1	51	-----A--A	AA-A-A-AA	-----A--	-----A--A	-----A--A	100
OMP-D-2	51	-----A--A	AA-A-A-AA	-----A--	-----A--A	-----A--A	100
OMP-Ba-1	51	-----A--A	AA-A-A-AA	-----A--	-----A--A	-----A--A	100
OMP-C	51	AA-AA-AAA	-----	---AAA-----	--A--AA	A-A-A--AA	100
OMP-D-1	51	-----A--A	AA-A-A-AA	-----A--	-----A--A	-----A--A	100
OMP-D-2	51	-----A--A	AA-A-A-AA	-----A--	-----A--A	-----A--A	100
OMP-Da	51	-----A--A	AA-A-A-AA	-----A--	-----A--A	-----A--A	100
OMP-E	51	-----A--A	AA-A-A-AA	-----A--	-----A--A	-----A--A	100
OMP-H	51	AAAAA-AAA	-----	---AAA-----	--A--AA	A-A-A--AA	100
OMP-I	51	AA-AA-AAA	-----	---AAA-----	--A--AA	A-A-A--AA	100
OMP-J	51	AA-AA-AAA	-----	---AAA-----	--A--AA	A-A-A--AA	100
OMP-K	51	AA-AA-AAA	-----	---AAA-----	--A--AA	A-A-A--AA	100
OMP-L1	51	-----A--A	AA-A-A-AA	-----A--	-----A--A	-----A--A	100
OMP-L2-1	51	-----A--A	AA-A-A-AA	-----A--	-----A--A	-----A--A	100
OMP-L2-3	51	-----A--A	AA-A-A-AA	-----A--	-----A--A	-----A--A	100
OMP-L3	51	AA-AA-AAA	-----	---AAA-----	--A--AA	A-A-A--AA	100
OMP-LGV	51	-----A--A	AA-A-A-AA	-----A--	-----A--A	-----A--A	100
		110	120	130	140	150	
OMP-A-1	101	-A-----	AAA-----	-----A--	A-----	AA--A--A	150
OMP-A-3	101	-A-----	AAA-----	-----A--	A-----	AA--A--A	150
OMP-D-1	101	-A--A-----	AAA-----	-----A--	AA--A--	-----A--	150
OMP-B-2	101	-A--A-----	AAA-----	-----A--	AA--A--	-----A--	150
OMP-Ba-1	101	-A--A-----	AAA-----	-----A--	AA--A--	-----A--	150
OMP-C	101	-A-----	AAA-----	-----A--	A-----	AA--A--A	150
OMP-D-1	101	-A--A-----	AAA-----	-----A--	AA--A--	-----A--	150
OMP-D-2	101	-A--A-----	AAA-----	-----A--	AA--A--	-----A--	150
OMP-Da	101	-A--A-----	AAA-----	-----A--	AA--A--	-----A--	150
OMP-E	101	-A--A-----	AAA-----	-----A--	AA--A--	-----A--	150
OMP-H	101	-A-----	AAA-----	-----A--	A-----	AA--A--A	150
OMP-I	101	-A-----	AAA-----	-----A--	A-----	AA--A--A	150
OMP-J	101	-A-----	AAA-----	-----A--	A-----	AA--A--A	150
OMP-K	101	-A-----	AAA-----	-----A--	A-----	AA--A--A	150

- 38 -

CLAIMS

1                   1. A method for evaluating a natural abundance sample for the presence of DNA  
2 from a target microorganism comprising the steps of:

3                   (a) combining the natural abundance sample with first and second primers, a  
4 nucleotide triphosphate feedstock mixture, a chain-terminating nucleotide triphosphate and a  
5 thermally stable polymerase enzyme which incorporates dideoxynucleotides into an extending  
6 nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of  
7 deoxynucleotides in an amplification mixture to form a reaction mixture, said first and second  
8 primers binding to the sense and antisense strands, respectively, and flanking a selected region  
9 within the target microorganism genome;

10                  (b) exposing the reaction mixture to a plurality of temperature cycles each of which  
11 includes at least a high temperature denaturation phase and a lower temperature extension phase,  
12 thereby producing a plurality of species of terminated fragments if DNA from the target  
13 microorganism is present in the natural abundance sample, each species of terminated fragment  
14 corresponding to a different incorporation position for the chain-terminating nucleotide  
15 triphosphate in the DNA of the target microorganism DNA; and

16                  (c) evaluating the terminated fragments produced to determine the incorporation  
17 positions of the chain-terminating nucleotide triphosphate.

1                   2. The method of claim 1, wherein at least one of the first and second primers is  
2 labeled with a fluorescent label.

1                   3. The method of claim 1, wherein the first and second primers are each  
2 labeled with a different fluorescent label.

3  
4                   4. The method of any of claims 1 to 3, wherein the chain terminating  
5 nucleotide triphosphate is present in a mole ratio to the corresponding nucleotide triphosphate of  
6 from 1:50 to 1:1000.

1                   5. The method of claim 4, wherein the mole ratio of the chain terminating  
2 nucleotide triphosphate to the corresponding nucleotide triphosphate is from 1:100 to 1:500.



- 39 -

1                   6.     The method according to any of claims 1 to 5, wherein the target  
2     microorganism is *Chlamydia trachomatis*.

1                   7.     The method according to claim 6, wherein the first and second primers are  
2     selected from among the group consisting of the oligonucleotides given by Seq. ID. Nos. 1-17.

1                   8.     The method according to any of claims 1 to 5, wherein the target  
2     microorganism is human immunodeficiency virus.

1                   9.     The method according to claim 8, wherein the first and second primers are  
2     selected from among the group consisting of the oligonucleotides given by Seq. ID. Nos. 18-20.

1                   10.    The method according to any of claims 1 to 5, wherein the target  
2     microorganism is human papilloma virus.

1                   11.    The method according to claim 10, wherein the first and second primers  
2     are selected from among the group consisting of the oligonucleotides given by Seq. ID. Nos. 21-  
3     22.

1                   12.    A composition comprising a mixture of four deoxynucleotide  
2     triphosphates and at least one dideoxynucleotide triphosphate corresponding to one of the four  
3     deoxynucleotide triphosphates, wherein the dideoxynucleotide triphosphate is present in a mole  
4     ratio to the corresponding deoxynucleotide triphosphate of from 1:50 to 1:500.

1                   13.    The composition according to claim 12, wherein the mole ratio is from  
2     1:100 to 1:300.

1                   14.    The composition according to claim 12 or 13, further comprising a  
2     thermally stable polymerase enzyme which incorporates dideoxynucleotides into an extending  
3     nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of  
4     deoxynucleotides.

- 40 -

- 1                   15.    A kit for detection of a target microorganism comprising, in packaged  
2 combination,  
3                   (a)    a pair of primers which bind to the sense and antisense strands,  
4 respectively, and flank a selected region within the genome target microorganism; and  
5                   (b)    a mixture of four deoxynucleotide triphosphates and at least  
6 dideoxynucleotide triphosphate corresponding to one of the four deoxynucleotide triphosphates,  
7 wherein the dideoxynucleotide triphosphate is present in a mole ratio to the corresponding  
8 deoxynucleotide triphosphate of from 1:50 to 1:1000.
- 1                   16.    The kit according to claim 15, wherein the mole ratio is from 1:100 to  
2 1:500.
- 1                   17.    The kit according to claim 15 or 16, further comprising a polymerase  
2 enzyme which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate  
3 which is no less than 0.4 times the rate of incorporation of deoxynucleotides.
- 1                   18.    The kit according to any of claims 15 to 17, wherein at least one of the  
2 primers is labeled with a fluorescent label.
- 1                   19.    The kit according to any of claims 15 to 17, wherein the primers are each  
2 labeled with a spectroscopically-distinct fluorescent label.
- 1                   20.    The kit according to any of claims 15 to 19, wherein the target  
2 microorganism is *Chlamydia trachomatis*.
- 1                   21.    The kit according to claim 20, wherein the first and second primers are  
2 selected from among the group consisting of the oligonucleotides given by Seq. ID. Nos. 1-17.
- 1                   22.    The kit according to any of claims 15 to 19, wherein the target  
2 microorganism is human immunodeficiency virus.

- 41 -

1                   23.    The kit according to claim 22, wherein the first and second primers are  
2   selected from among the group consisting of the oligonucleotides given by Seq. ID. Nos. 18-20.

1                   24.    The kit according to any of claims 15 to 19, wherein the target  
2   microorganism is human papilloma virus.

1                   25.    The kit according to claim 24, wherein the first and second primers are  
2   selected from among the group consisting of the oligonucleotides given by Seq. ID. Nos. 21-22.

1                   26.    A method for evaluating a natural abundance sample for the presence of  
2   DNA from a target microorganism comprising the steps of:

3           (a)    combining each of from one to three aliquots of the natural abundance sample  
4   with first and second primers, a nucleotide triphosphate feedstock mixture, a single chain-  
5   terminating nucleotide triphosphate and a thermally stable polymerase enzyme which  
6   incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less  
7   than 0.4 times the rate of incorporation of deoxynucleotides in an amplification mixture to form  
8   a reaction mixture, said first and second primers binding to the sense and antisense strands,  
9   respectively, and flanking a selected region within the target microorganism genome, wherein  
10   the chain terminating nucleotide triphosphate added to each aliquot is different from that added  
11   to the other aliquots;

12           (b)    exposing the reaction mixture to a plurality of temperature cycles each of which  
13   includes at least a high temperature denaturation phase and a lower temperature extension phase,  
14   thereby producing a plurality of species of terminated fragments if DNA from the target  
15   microorganism is present in the natural abundance sample, each species of terminated fragment  
16   corresponding to a different incorporation position for the chain-terminating nucleotide  
17   triphosphate in the DNA of the target microorganism DNA; and

18           (c)    evaluating the terminated fragments produced to determine the incorporation  
19   positions of the chain-terminating nucleotide triphosphate.

## INTERNATIONAL SEARCH REPORT

Intern al Application No

PCT/US 97/07133

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 02212 A (UNIV PARTNERSHIPS PTY LTD) 4 February 1993 see the whole document ---	1-26
Y	ANALYTICAL BIOCHEMISTRY, vol. 216, no. 1, 1 January 1994, pages 1-14, XP000420647 VENIGALLA B RAO: "DIRECT SEQUENCING OF POLYMERASE CHAIN REACTION-AMPLIFIED DNA" see the whole document ---	1-26
Y	ANALYTICAL BIOCHEMISTRY, vol. 224, no. 1, 1 January 1995, pages 117-121, XP000486746 WIEMANN S ET AL: "SIMULTANEOUS ON-LINE DNA SEQUENCING ON BOTH STRANDS WITH TWO FLUORESCENT DYES" see the whole document ---	1-26

-/-

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"A" document member of the same patent family

Date of the actual completion of the international search

26 August 1997

Date of mailing of the international search report

09.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Hagenmaier, S

## INTERNATIONAL SEARCH REPORT

Intern: Application No

PCT/US 97/07133

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J. CLIN. MICROBIOL., vol. 30, no. 9, 1992, pages 2241-2245, XP002038923 MAHONY ET AL.: "Confirmatory polymerase chain reaction testing for chlamydia trachomatis in first-void urine from asymptomatic and symptomatic men" cited in the application see the whole document ---	6,7,20, 21
Y	WO 92 18650 A (BAXTER DIAGNOSTICS INC) 29 October 1992 See oligonucleotides Seq. ID. 3,4 and 9. ---	8,9,22, 23
Y	US 5 283 171 A (MANOS M MICHELE ET AL) 1 February 1994 see oligonucleotide Q56359, disclosure, page 6 and oligonucleotide Q56341, claim 5, page 4. ---	10,11, 24,25
A	EP 0 655 506 A (HARVARD COLLEGE) 31 May 1995 see the whole document ---	1-26
A	NATURE, vol. 376, 31 August 1995, page 796/797 XP000606193 REEVE M A ET AL: "A NOVEL THERMOSTABLE POLYMERASE FOR DNA SEQUENCING" cited in the application see the whole document ---	1-26
A	PCR METHODS & APPLICATIONS, vol. 3, no. 5, April 1994, pages S107-S112, XP000606764 KRETZ K ET AL: "CYCLE SEQUENCING" see the whole document ---	1-26
A	WO 93 08305 A (HOLMES MICHAEL JOHN ;DYNAL AS (GB)) 29 April 1993 see the whole document -----	1-26

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/07133

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9302212 A	04-02-93	AU 660484 B CA 2114124 A EP 0595982 A JP 7500004 T	29-06-95 04-02-93 11-05-94 05-01-95
WO 9218650 A	29-10-92	AU 656965 B AU 1690492 A EP 0533906 A JP 5508323 T	23-02-95 17-11-92 31-03-93 25-11-93
US 5283171 A	01-02-94	US 5182377 A AT 138108 T AU 645483 B AU 4401189 A DE 68926507 D DE 68926507 T EP 0433396 A JP 4500910 T US 5447839 A WO 9002821 A US 5639871 A US 5527898 A	26-01-93 15-06-96 20-01-94 02-04-90 20-06-96 16-01-97 26-06-91 20-02-92 05-09-95 22-03-90 17-06-97 18-06-96
EP 0655506 A	31-05-95	US 5614365 A AT 143057 T AU 4193396 A DE 29513622 U DE 29513639 U DE 69400567 D DE 69400567 T DE 655506 T EP 0727496 A ES 2072238 T FI 971611 A JP 8205874 A WO 9612042 A ZA 9508761 A	25-03-97 15-10-96 06-05-96 19-10-95 19-10-95 24-10-96 06-02-97 28-09-95 21-08-96 16-07-95 13-06-97 13-08-96 25-04-96 13-05-96
WO 9308305 A	29-04-93	AU 2787692 A	21-05-93